Meridian Investment Counsel Inc. Gilead Sciences, Inc. Transaction History

Meridian Investment Counsel Inc.

  • $329 Million
  • Q4 2024

A detailed history of Meridian Investment Counsel Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Meridian Investment Counsel Inc. holds 21,367 shares of GILD stock, worth $2.21 Million. This represents 0.6% of its overall portfolio holdings.

Number of Shares
21,367
Previous 21,572 0.95%
Holding current value
$2.21 Million
Previous $1.81 Million 9.13%
% of portfolio
0.6%
Previous 0.56%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025
SELL
$83.95 - $97.9 $17,209 - $20,069
-205 Reduced 0.95%
21,367 $1.97 Million
Q3 2024

Nov 06, 2024
SELL
$66.59 - $83.99 $139,839 - $176,379
-2,100 Reduced 8.87%
21,572 $1.81 Million
Q2 2024

Jul 19, 2024
SELL
$63.15 - $72.88 $11,998 - $13,847
-190 Reduced 0.8%
23,672 $1.62 Million
Q1 2024

May 13, 2024
SELL
$71.58 - $87.29 $14,101 - $17,196
-197 Reduced 0.82%
23,862 $1.75 Million
Q4 2023

Feb 09, 2024
SELL
$73.27 - $83.09 $25,644 - $29,081
-350 Reduced 1.43%
24,059 $1.95 Million
Q3 2023

Nov 03, 2023
SELL
$73.94 - $80.67 $59,152 - $64,536
-800 Reduced 3.17%
24,409 $1.83 Million
Q1 2023

May 05, 2023
SELL
$77.31 - $88.08 $15,462 - $17,616
-200 Reduced 0.79%
25,209 $2.09 Million
Q4 2022

Feb 06, 2023
SELL
$62.32 - $89.47 $38,950 - $55,918
-625 Reduced 2.4%
25,409 $2.18 Million
Q3 2022

Nov 08, 2022
SELL
$59.54 - $68.01 $7,442 - $8,501
-125 Reduced 0.48%
26,034 $1.61 Million
Q2 2022

Aug 11, 2022
SELL
$57.72 - $65.01 $65,916 - $74,241
-1,142 Reduced 4.18%
26,159 $1.62 Million
Q4 2021

Feb 14, 2022
SELL
$64.88 - $73.64 $17,842 - $20,251
-275 Reduced 1.0%
27,301 $1.98 Million
Q3 2021

Oct 27, 2021
SELL
$67.69 - $73.03 $37,229 - $40,166
-550 Reduced 1.96%
27,576 $1.93 Million
Q2 2021

Jul 23, 2021
BUY
$63.47 - $69.35 $6,029 - $6,588
95 Added 0.34%
28,126 $1.94 Million
Q1 2021

May 03, 2021
SELL
$60.0 - $68.46 $6,000 - $6,845
-100 Reduced 0.36%
28,031 $1.81 Million
Q4 2020

Feb 03, 2021
SELL
$56.65 - $64.55 $31,157 - $35,502
-550 Reduced 1.92%
28,131 $1.64 Million
Q3 2020

Oct 23, 2020
SELL
$62.1 - $78.08 $6,210 - $7,808
-100 Reduced 0.35%
28,681 $1.81 Million
Q2 2020

Aug 05, 2020
BUY
$72.34 - $84.0 $14,829 - $17,220
205 Added 0.72%
28,781 $2.21 Million
Q1 2020

Apr 30, 2020
SELL
$62.63 - $80.22 $43,841 - $56,154
-700 Reduced 2.39%
28,576 $2.14 Million
Q4 2019

Feb 06, 2020
SELL
$61.62 - $67.78 $18,486 - $20,334
-300 Reduced 1.01%
29,276 $1.9 Million
Q3 2019

Oct 25, 2019
SELL
$62.51 - $69.0 $9,376 - $10,350
-150 Reduced 0.5%
29,576 $1.88 Million
Q2 2019

Aug 13, 2019
SELL
$61.87 - $69.38 $680 - $763
-11 Reduced 0.04%
29,726 $2.01 Million
Q1 2019

May 06, 2019
SELL
$62.53 - $70.05 $43,771 - $49,035
-700 Reduced 2.3%
29,737 $1.93 Million
Q4 2018

Feb 13, 2019
SELL
$60.54 - $79.0 $18,162 - $23,700
-300 Reduced 0.98%
30,437 $1.9 Million
Q3 2018

Nov 05, 2018
SELL
$71.28 - $78.92 $8,553 - $9,470
-120 Reduced 0.39%
30,737 $2.37 Million
Q2 2018

Aug 08, 2018
BUY
$64.88 - $75.68 $3,244 - $3,784
50 Added 0.16%
30,857 $2.19 Million
Q1 2018

May 14, 2018
BUY
$72.84 - $88.8 $222,162 - $270,840
3,050 Added 10.99%
30,807 $2.32 Million
Q4 2017

Feb 13, 2018
BUY
$71.15 - $83.52 $363,576 - $426,787
5,110 Added 22.56%
27,757 $1.99 Million
Q3 2017

Nov 08, 2017
BUY
$72.11 - $85.47 $57,688 - $68,376
800 Added 3.66%
22,647 $1.84 Million
Q2 2017

Aug 14, 2017
BUY
N/A
21,847
21,847 $1.55 Million

Others Institutions Holding GILD

# of Institutions
2,030
Shares Held
1.01B
Call Options Held
10M
Put Options Held
8.9M
View Full List

About GILEAD SCIENCES, INC.

GILD Quotes by TradingView
  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $129B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Meridian Investment Counsel Inc. Portfolio

Follow Meridian Investment Counsel Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meridian Investment Counsel Inc., based on Form 13F filings with the SEC.

News

Stay updated on Meridian Investment Counsel Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email